Ulkan Vaishampayan News Today

- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on...

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the...

- ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types - - Company to Host Investor Webcast on June

ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficacy levels comparable to intravenous (IV) docetaxel Based on strong

- Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation - - Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin), the companys novel,...

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the companys novel,...

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered